F. J. Cleton

3.7k total citations
64 papers, 2.8k citations indexed

About

F. J. Cleton is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, F. J. Cleton has authored 64 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 14 papers in Molecular Biology and 11 papers in Pathology and Forensic Medicine. Recurrent topics in F. J. Cleton's work include Bone health and treatments (8 papers), Immunotherapy and Immune Responses (6 papers) and Cancer Diagnosis and Treatment (6 papers). F. J. Cleton is often cited by papers focused on Bone health and treatments (8 papers), Immunotherapy and Immune Responses (6 papers) and Cancer Diagnosis and Treatment (6 papers). F. J. Cleton collaborates with scholars based in Netherlands, United Kingdom and United States. F. J. Cleton's co-authors include Susanne Osanto, Nir I. Weijl, Adam Turnbull, Clement A. Finch, O. L. M. Bijvoet, Eef G.W.M. Lentjes, H. G. Kwa, J. Hermans, E Engelsman and G.H. Blijham and has published in prestigious journals such as The Lancet, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

F. J. Cleton

63 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
F. J. Cleton Netherlands 27 1.1k 570 417 396 367 64 2.8k
Timo Koivula Finland 29 617 0.6× 657 1.2× 877 2.1× 186 0.5× 445 1.2× 88 3.4k
Stephen Frytak United States 31 1.9k 1.7× 627 1.1× 493 1.2× 194 0.5× 1.4k 3.8× 113 3.7k
Sumio Kawata Japan 45 984 0.9× 1.8k 3.1× 451 1.1× 420 1.1× 452 1.2× 181 6.1k
D. Amadori Italy 35 1.8k 1.6× 739 1.3× 518 1.2× 157 0.4× 1.1k 2.9× 173 3.9k
Erkan Topuz Türkiye 28 957 0.9× 626 1.1× 295 0.7× 94 0.2× 473 1.3× 113 2.4k
Patrick D. Walker United States 42 498 0.4× 1.4k 2.5× 767 1.8× 188 0.5× 777 2.1× 122 5.1k
Janardan D. Khandekar United States 24 1.3k 1.2× 535 0.9× 397 1.0× 95 0.2× 481 1.3× 78 3.3k
Yoshikazu Murawaki Japan 35 528 0.5× 1.0k 1.8× 339 0.8× 153 0.4× 380 1.0× 196 4.1k
Anne Dawnay United Kingdom 27 298 0.3× 838 1.5× 317 0.8× 175 0.4× 342 0.9× 91 3.4k
R.D. Bulbrook United Kingdom 32 1.2k 1.1× 462 0.8× 323 0.8× 164 0.4× 413 1.1× 137 3.4k

Countries citing papers authored by F. J. Cleton

Since Specialization
Citations

This map shows the geographic impact of F. J. Cleton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. J. Cleton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. J. Cleton more than expected).

Fields of papers citing papers by F. J. Cleton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. J. Cleton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. J. Cleton. The network helps show where F. J. Cleton may publish in the future.

Co-authorship network of co-authors of F. J. Cleton

This figure shows the co-authorship network connecting the top 25 collaborators of F. J. Cleton. A scholar is included among the top collaborators of F. J. Cleton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. J. Cleton. F. J. Cleton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Pauwels, E.K.J., et al.. (2000). Positron-emission tomography with [18F]fluorodeoxyglucose. Journal of Cancer Research and Clinical Oncology. 126(10). 549–559. 133 indexed citations
3.
Weijl, Nir I., et al.. (1998). Cisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients. Annals of Oncology. 9(12). 1331–1337. 176 indexed citations
4.
Valkema, Roelf, et al.. (1996). The diagnostic utility of somatostatin receptor scintigraphy in oncology. Journal of Cancer Research and Clinical Oncology. 122(9). 513–532. 15 indexed citations
5.
Guinee, Vincent F., Håkan Olsson, Henrik Møller, et al.. (1995). Effect of Pregnancy on Prognosis for Young Women With Breast Cancer. Obstetrical & Gynecological Survey. 50(1). 6–7. 11 indexed citations
6.
Wit, Sanne de & F. J. Cleton. (1994). Hypercalcemia in patients with breast cancer: a survival study. Journal of Cancer Research and Clinical Oncology. 120(10). 610–614. 24 indexed citations
7.
Weijl, Nir I., D van der Harst, Anneke Brand, et al.. (1993). Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment.. Journal of Clinical Oncology. 11(7). 1376–1383. 71 indexed citations
8.
Vasen, Hans F. A., L.V.A.M. Beex, F. J. Cleton, et al.. (1993). Clinical heterogeneity of hereditary breast cancer and its impact on screening protocols: The dutch experience on 24 families under surveillance. European Journal of Cancer. 29(8). 1111–1114. 9 indexed citations
9.
Eb, M.M. van der, et al.. (1993). Reverse smoking as a risk factor for palatal cancer: A cross‐sectional study in rural andhra pradesh, india. International Journal of Cancer. 54(5). 754–758. 21 indexed citations
10.
Kroon, Hidde M., O. L. M. Bijvoet, F. J. Cleton, et al.. (1993). Palliative pamidronate treatment in patients with bone metastases from breast cancer.. Journal of Clinical Oncology. 11(3). 491–498. 164 indexed citations
11.
Cleton, F. J., et al.. (1992). Febrile neutropenic events in cancer patients Treatment for fever and neutropenia in young adult patients during intensive chemotherapy for solid tumours. Journal of Cancer Research and Clinical Oncology. 118(5). 395–399. 7 indexed citations
12.
Zwinderman, Aeilko H., Neil K. Aaronson, J. Hermans, et al.. (1991). The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. European Journal of Cancer and Clinical Oncology. 27(5). 544–549. 78 indexed citations
13.
Stoter, G., Steinar Aamdal, Sjoerd Rodenhuis, et al.. (1991). Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study.. Journal of Clinical Oncology. 9(9). 1687–1691. 42 indexed citations
14.
Cleton, F. J., et al.. (1989). Effect of Long-Term Bisphosphonate Treatment on Morbidity Due To Bone Metastases in Breast Cancer Patients. Recent results in cancer research. 116. 73–78. 14 indexed citations
15.
Stoter, G., Eitan Shiloni, S. Gundersen, et al.. (1989). Alternating recombinant human interleukin-2 and dacarbazine in advanced melanoma. A multicentric phase II study. Cancer Treatment Reviews. 16. 59–63. 10 indexed citations
16.
Osanto, Susanne, et al.. (1989). in vivo effects of combination treatment with recombinant interferon‐gamma and ‐alpha in metastatic melanoma. International Journal of Cancer. 43(6). 1001–1006. 25 indexed citations
17.
Cleton, F. J., et al.. (1989). Cancer in The Netherlands. European Journal of Cancer and Clinical Oncology. 25(4). 767–771. 33 indexed citations
18.
Bijvoet, O. L. M., J. Hermans, H.I.J. Harinck, et al.. (1987). REDUCED MORBIDITY FROM SKELETAL METASTASES IN BREAST CANCER PATIENTS DURING LONG-TERM BISPHOSPHONATE (APD) TREATMENT. The Lancet. 330(8566). 983–985. 162 indexed citations
19.
Cleton, F. J., D. Crowther, & J. S. Malpas. (1974). Advances in acute leukaemia. Elsevier eBooks. 20 indexed citations
20.
Balner, H., et al.. (1968). TESTING OF ANTI-HUMAN LYMPHOCYTE SERA IN CHIMPANZEES AND LOWER PRIMATES. The Lancet. 291(7532). 19–22. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Timo Koivula Breakdown of academic impact, for papers by Stephen Frytak Breakdown of academic impact, for papers by Sumio Kawata Breakdown of academic impact, for papers by D. Amadori Breakdown of academic impact, for papers by Erkan Topuz Breakdown of academic impact, for papers by Patrick D. Walker Breakdown of academic impact, for papers by Janardan D. Khandekar Breakdown of academic impact, for papers by Yoshikazu Murawaki Breakdown of academic impact, for papers by Anne Dawnay Breakdown of academic impact, for papers by R.D. Bulbrook
Rankless by CCL
2026